R01DA054553

Cannabis Use, Prep, and HIV Transmission Risk Among Black MSM in Chicago - Project Summary

Black gay, bisexual, and other men who have sex with men (MSM) face a disproportionate burden of HIV. Focused, high-coverage Prep in populations heavily impacted by HIV, such as Black MSM, could rapidly reduce new HIV acquisition rates. However, its uptake among at-risk populations, especially Black MSM, has been limited.

Therefore, we propose to conduct urgently needed research on Prep in a cohort of Black MSM, including on the impact of relevant behaviors, particularly cannabis use, which is highly prevalent in Black MSM. Research on the impact of cannabis use on Prep has achieved conflicting results, and it has not been rigorously studied in Black MSM.

Therefore, the proposed R01 study will assess cross-sectional and longitudinal associations between cannabis use and Prep outcomes (e.g., use, adherence) and HIV transmission risk (e.g., biological inflammation, sexual risk behavior) using event-level and objective biomarker data among HIV-negative Black MSM.

To address these specific aims, we will conduct the Networks and Neighborhoods (N2) Cannabis Prep Study in Chicago, IL. We will follow 250 HIV-negative participants from the original N2 cohort for an additional one-year period with 3 study waves. We will use innovative and rigorous methods to collect additional data, such as ecological momentary assessment methods and objective measures of cannabis use, Prep use, and immune function over 14-day periods at each wave.

Potential findings can impact intervention development and implementation, as well as inform policy to increase Prep uptake and adherence, address substance use, and decrease HIV transmission rates and disparities.

The Trustees Of Columbia University In The City Of New York

TO SUPPORT BASIC AND CLINICAL NEUROSCIENCE, BIOMEDICAL, BEHAVIORAL AND SOCIAL SCIENCE, EPIDEMIOLOGIC, HEALTH SERVICES AND HEALTH DISPARITY RESEARCH. TO DEVELOP NEW KNOWLEDGE AND APPROACHES RELATED TO THE PREVENTION, DIAGNOSIS, TREATMENT, ETIOLOGY, AND CONSEQUENCES OF DRUG ABUSE AND ADDICTION, INCLUDING HIV/AIDS. TO SUPPORT RESEARCH TRAINING AND RESEARCH SCIENTIST DEVELOPMENT. TO SUPPORT DISSEMINATION OF RESEARCH FINDINGS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) LEGISLATION IS INTENDED TO EXPAND AND IMPROVE THE SBIR PROGRAMS TO EMPHASIZE AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF TECHNOLOGY DEVELOPED THROUGH FEDERAL SBIR RESEARCH AND DEVELOPMENT, INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN THE SBIR PROGRAM. THE LEGISLATION INTENDS THAT THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.

93.855 - Allergy and Infectious Diseases Research

National Institute on Drug Abuse (NIDA) [HHS - NIH]

National Institute of Allergy and Infectious Diseases (NIAID) [HHS - NIH]

New York, New York 100323727 United States

Single Zip Code

PrEP for HIV Prevention among Substance Using Populations (R01 - Clinical Trial Optional) (RFA-DA-21-024)

Amendment Since initial award the total obligations have increased 854% from $380,101 to $3,624,329.